Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Michael Duffy
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Procedures
Physiology
Concepts & Ideas
Sign-in to see full Profile
Network (preview)
23
McDermott, Enda
22
O'Higgins, Niall
16
Maguire, Teresa
15
Hill, A D K
13
McDermott, Enda
10
O'Donovan, Norma
9
Gallagher, William
8
Brennan, Donal
7
Crown, John
7
O'Higgins, Niall
5
Landberg, Göran
5
Ryan, Bríd
5
Shering, SG
5
McGowan, Patricia
4
O'Brien, Sallyann
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Michael Duffy (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Browne B C; O'Brien N; Duffy M J; Crown J; O'Donovan N
HER-2 signaling and inhibition in breast cancer.
Current cancer drug targets 2009;9(3):419-38.
-
2009: Duffy Michael J; McKiernan Eadaoin; O'Donovan Norma; McGowan Patricia M
The role of ADAMs in disease pathophysiology.
Clinica chimica acta; international journal of clinical chemistry 2009;403(1-2):31-6.
-
2009: Lanigan Fiona; McKiernan Eadaoin; Brennan Donal J; Hegarty Shauna; Millikan Robert C; McBryan Jean; Jirstrom Karin; Landberg Goran; Martin Finian; Duffy Michael J; Gallagher William M
Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
International journal of cancer. Journal international du cancer 2009;124(9):2088-97.
-
2009: Duffy M J; Napieralski R; Martens J W M; Span P N; Spyratos F; Sweep F C G J; Brunner N; Foekens J A; Schmitt M;
Methylated genes as new cancer biomarkers.
European journal of cancer (Oxford, England : 1990) 2009;45(3):335-46.
-
2009: Sturgeon C M; Lai L C; Duffy M J
Serum tumour markers: how to order and interpret them.
BMJ (Clinical research ed.) 2009;339():b3527.
-
2009: Markey G C; Cullen R; Diggin P; Hill A D K; Mc Dermott E W; O'Higgins N J; Duffy M J
Estrogen receptor-beta mRNA is associated with adverse outcome in patients with breast cancer.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2009;30(4):171-5.
-
2008: Sturgeon Catharine M; Duffy Michael J; Stenman Ulf-Håkan; Lilja Hans; Brünner Nils; Chan Daniel W; Babaian Richard; Bast Robert C; Dowell Barry; Esteva Francisco J; Haglund Caj; Harbeck Nadia; Hayes Daniel F; Holten-Andersen Mads; Klee George G; Lamerz Rolf; Looijenga Leendert H; Molina Rafael; Nielsen Hans Jørgen; Rittenhouse Harry; Semjonow Axel; Shih Ie-Ming; Sibley Paul; Sölétormos György; Stephan Carsten; Sokoll Lori; Hoffman Barry R; Diamandis Eleftherios P;
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Clinical chemistry 2008;54(12):e11-79.
-
2008: Duffy Michael J; Crown John
A personalized approach to cancer treatment: how biomarkers can help.
Clinical chemistry 2008;54(11):1770-9.
-
2008: McGowan P M; Duffy M J
Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(9):1566-72.
-
2008: McGowan P M; McKiernan E; Bolster F; Ryan B M; Hill A D K; McDermott E W; Evoy D; O'Higgins N; Crown J; Duffy M J
ADAM-17 predicts adverse outcome in patients with breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(6):1075-81.
-
2008: Krajewska Maryla; Kitada Shinichi; Winter Jane N; Variakojis Daina; Lichtenstein Alan; Zhai Dayong; Cuddy Michael; Huang Xianshu; Luciano Frederic; Baker Cheryl H; Kim Hoguen; Shin Eunah; Kennedy Susan; Olson Allen H; Badzio Andrzej; Jassem Jacek; Meinhold-Heerlein Ivo; Duffy Michael J; Schimmer Aaron D; Tsao Ming; Brown Ewan; Sawyers Anne; Andreeff Michael; Mercola Dan; Krajewski Stan; Reed John C
Bcl-B expression in human epithelial and nonepithelial malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):3011-21.
-
2008: Brennan Donal J; Rexhepaj Elton; O'Brien Sallyann L; McSherry Elaine; O'Connor Darran P; Fagan Ailís; Culhane Aedín C; Higgins Desmond G; Jirstrom Karin; Millikan Robert C; Landberg Goran; Duffy Michael J; Hewitt Stephen M; Gallagher William M
Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(9):2681-9.
-
2008: Duffy M J; McGowan P M; Gallagher W M
Cancer invasion and metastasis: changing views.
The Journal of pathology 2008;214(3):283-93.
-
2008: Rexhepaj Elton; Brennan Donal J; Holloway Peter; Kay Elaine W; McCann Amanda H; Landberg Goran; Duffy Michael J; Jirstrom Karin; Gallagher William M
Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
Breast cancer research : BCR 2008;10(5):R89.
-
2007: Duffy M J; van Dalen A; Haglund C; Hansson L; Holinski-Feder E; Klapdor R; Lamerz R; Peltomaki P; Sturgeon C; Topolcan O
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
European journal of cancer (Oxford, England : 1990) 2007;43(9):1348-60.
-
2007: Brennan Donal J; Kelly Catherine; Rexhepaj Elton; Dervan Peter A; Duffy Michael J; Gallagher William M
Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer.
Cancer genomics & proteomics 2007;4(3):121-34.
-
2007: McGowan Patricia M; Ryan Bríd M; Hill Arnold D K; McDermott Enda; O'Higgins Niall; Duffy Michael J
ADAM-17 expression in breast cancer correlates with variables of tumor progression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2335-43.
-
2007: Duffy Michael J; O'Donovan Norma; Brennan Donal J; Gallagher William M; Ryan Bríd M
Survivin: a promising tumor biomarker.
Cancer letters 2007;249(1):49-60.
-
2007: O'Brien Sallyann L; Fagan Ailís; Fox Edward J P; Millikan Robert C; Culhane Aedín C; Brennan Donal J; McCann Amanda H; Hegarty Shauna; Moyna Siobhan; Duffy Michael J; Higgins Desmond G; Jirström Karin; Landberg Göran; Gallagher William M
CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer.
International journal of cancer. Journal international du cancer 2007;120(7):1434-43.
-
2007: Culleton Jane; O'Brien Neil; Ryan Bríd M; Hill Arnold D K; McDermott Enda; O'Higgins Niall; Duffy Michael J
Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer.
International journal of cancer. Journal international du cancer 2007;120(5):1087-92.
-
2007: Lau Thomas Y K; O'Connor Darran P; Brennan Donal J; Duffy Michael J; Pennington Stephen R; Gallagher William M
Breast cancer proteomics: clinical perspectives.
Expert opinion on biological therapy 2007;7(2):209-19.
-
2007: O'Brien Neil; O'Donovan Norma; Foley Deirdre; Hill Arnold D K; McDermott Enda; O'Higgins Niall; Duffy Michael J
Use of a panel of novel genes for differentiating breast cancer from non-breast tissues.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2007;28(6):312-7.
-
2006: Brennan Donal J; Jirstrom Karin; Kronblad Asa; Millikan Robert C; Landberg Goran; Duffy Michael J; Rydén Lisa; Gallagher William M; O'Brien Sallyann L
CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6421-31.
-
2006: Ryan B M; Konecny G E; Kahlert S; Wang H-J; Untch M; Meng G; Pegram M D; Podratz K C; Crown J; Slamon D J; Duffy M J
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(4):597-604.
-
2006: Savinov Alexei Y; Remacle Albert G; Golubkov Vladislav S; Krajewska Maryla; Kennedy Susan; Duffy Michael J; Rozanov Dmitri V; Krajewski Stan; Strongin Alex Y
Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients.
Cancer research 2006;66(5):2716-24.
-
2006: Duffy Michael J
Serum tumor markers in breast cancer: are they of clinical value?
Clinical chemistry 2006;52(3):345-51.
-
2006: Buggy Y; Maguire T M; McDermott E; Hill A D K; O'Higgins N; Duffy M J
Ets2 transcription factor in normal and neoplastic human breast tissue.
European journal of cancer (Oxford, England : 1990) 2006;42(4):485-91.
-
2006: Duffy M J
Estrogen receptors: role in breast cancer.
Critical reviews in clinical laboratory sciences 2006;43(4):325-47.
-
2005: Molina Rafael; Barak Vivian; van Dalen Arie; Duffy Michael J; Einarsson Roland; Gion Massimo; Goike Helenka; Lamerz Rolf; Nap Marius; Sölétormos György; Stieber Petra
Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005;26(6):281-93.
-
2005: Roddam Andrew W; Duffy Michael J; Hamdy Freddie C; Ward Anthony Milford; Patnick Julietta; Price Christopher P; Rimmer Janet; Sturgeon Cathie; White Peter; Allen Naomi E;
Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.
European urology 2005;48(3):386-99; discussion 398-9.
-
2005: Krajewska Maryla; Kim Hoguen; Shin Eunah; Kennedy Susan; Duffy Michael J; Wong Yick F; Marr David; Mikolajczyk Jowita; Shabaik Ahmed; Meinhold-Heerlein Ivo; Huang Xianshu; Banares Steven; Hedayat Hirad; Reed John C; Krajewski Stan
Tumor-associated alterations in caspase-14 expression in epithelial malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5462-71.
-
2005: Brennan Donal J; O'Brien Sallyann L; Fagan Ailís; Culhane Aedín C; Higgins Desmond G; Duffy Michael J; Gallagher William M
Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response.
Expert opinion on biological therapy 2005;5(8):1069-83.
-
2005: Kelly Louise M; Buggy Yvonne; Hill Arnold; O'Donovan Norma; Duggan Catherine; McDermott Enda W; O'Higgins Niall J; Young Leonie; Duffy Michael J
Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005;26(4):213-6.
-
2005: Grebenchtchikov N; Maguire T M; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep C G J; Duffy M J
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Oncology reports 2005;14(1):235-9.
-
2005: O'Brien Neil A; O'Donovan Norma; Ryan Bríd; Hill Arnold D K; McDermott Enda; O'Higgins Niall; Duffy Michael J
Mammaglobin a in breast cancer: existence of multiple molecular forms.
International journal of cancer. Journal international du cancer 2005;114(4):623-7.
-
2005: Duffy Michael J
Predictive markers in breast and other cancers: a review.
Clinical chemistry 2005;51(3):494-503.
-
2005: Ryan B; O'Donovan N; Browne B; O'Shea C; Crown J; Hill A D K; McDermott E; O'Higgins N; Duffy M J
Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer.
British journal of cancer 2005;92(1):120-4.
-
2004: Buggy Y; Maguire T M; McGreal G; McDermott E; Hill A D K; O'Higgins N; Duffy M J
Overexpression of the Ets-1 transcription factor in human breast cancer.
British journal of cancer 2004;91(7):1308-15.
-
2004: Duffy Michael J
Evidence for the clinical use of tumour markers.
Annals of clinical biochemistry 2004;41(Pt 5):370-7.
-
2004: Duffy M J; Duggan C
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Clinical biochemistry 2004;37(7):541-8.
-
2004: Troy A M; Sheahan K; Mulcahy H E; Duffy M J; Hyland J M P; O'Donoghue D P
Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression.
European journal of cancer (Oxford, England : 1990) 2004;40(10):1610-6.
-
2004: Duffy Michael J; Duggan Catherine; Keane Rachel; Hill Arnold D K; McDermott Enda; Crown John; O'Higgins Niall
High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer.
Clinical chemistry 2004;50(3):559-63.
-
2004: Duffy Michael J
The urokinase plasminogen activator system: role in malignancy.
Current pharmaceutical design 2004;10(1):39-49.
-
2003: O'Shea Caroline; McKie Norman; Buggy Yvonne; Duggan Catherine; Hill Arnold D K; McDermott Enda; O'Higgins Niall; Duffy Michael J
Expression of ADAM-9 mRNA and protein in human breast cancer.
International journal of cancer. Journal international du cancer 2003;105(6):754-61.
-
2003: Duffy M J; van Dalen A; Haglund C; Hansson L; Klapdor R; Lamerz R; Nilsson O; Sturgeon C; Topolcan O
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.
European journal of cancer (Oxford, England : 1990) 2003;39(6):718-27.
-
2003: Greene L M; Twal W O; Duffy M J; McDermott E W; Hill A D; O'Higgins N J; McCann A H; Dervan P A; Argraves W S; Gallagher W M
Elevated expression and altered processing of fibulin-1 protein in human breast cancer.
British journal of cancer 2003;88(6):871-8.
-
2003: O'Donovan Norma; Crown John; Stunell Helen; Hill Arnold D K; McDermott Enda; O'Higgins Niall; Duffy Michael J
Caspase 3 in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):738-42.
-
2002: O'Brien Neil; Maguire Teresa M; O'Donovan Norma; Lynch Niamh; Hill Arnold D K; McDermott Enda; O'Higgins Niall; Duffy Michael J
Mammaglobin a: a promising marker for breast cancer.
Clinical chemistry 2002;48(8):1362-4.
-
2002: Duffy Michael J
Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
Clinical chemistry 2002;48(8):1194-7.
-
2002: Duffy Michael J
Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
Biochemical Society transactions 2002;30(2):207-10.
-
2001: Duffy M J
Biochemical markers in breast cancer: which ones are clinically useful?
Clinical biochemistry 2001;34(5):347-52.
-
2001: Duffy M J
Clinical uses of tumor markers: a critical review.
Critical reviews in clinical laboratory sciences 2001;38(3):225-62.
-
2001: Cullen R; Maguire T M; McDermott E W; Hill A D; O'Higgins N J; Duffy M J
Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(9):1118-22.
-
2001: Price C P; Allard J; Davies G; Dawnay A; Duffy M J; France M; Mandarino G; Ward A M; Patel B; Sibley P; Sturgeon C
Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer.
Annals of clinical biochemistry 2001;38(Pt 3):188-216.
-
2001: Duffy M J
Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?
Clinical chemistry 2001;47(4):624-30.
-
2000: Duffy M J; Shering S; Sherry F; McDermott E; O'Higgins N
CA 15-3: a prognostic marker in breast cancer.
The International journal of biological markers 2000;15(4):330-3.
-
2000: Hanemaaijer R; Verheijen J H; Maguire T M; Visser H; Toet K; McDermott E; O'Higgins N; Duffy M J
Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors.
International journal of cancer. Journal international du cancer 2000;86(2):204-7.
-
2000: Remacle A; McCarthy K; Noël A; Maguire T; McDermott E; O'Higgins N; Foidart J M; Duffy M J
High levels of TIMP-2 correlate with adverse prognosis in breast cancer.
International journal of cancer. Journal international du cancer 2000;89(2):118-21.
-
2000: Maguire T; Chin D; Soutar D; Duffy M J
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
International journal of cancer. Journal international du cancer 2000;85(4):457-9.
-
2000: Cullen R; MaGuire T; Diggin P; Hill A; McDermott E; O'Higgins N; Duffy M J
Detection of estrogen receptor-beta mRNA in breast cancer using RT-PCR.
The International journal of biological markers 2000;15(1):114-5.
-
2000: Duffy M J; Maguire T M; Hill A; McDermott E; O'Higgins N
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis.
Breast cancer research : BCR 2000;2(4):252-7.
-
1999: Duffy M J
CA 15-3 and related mucins as circulating markers in breast cancer.
Annals of clinical biochemistry 1999;36 ( Pt 5)():579-86.
-
1999: Duffy M J; Maguire T M; McDermott E W; O'Higgins N
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
Journal of surgical oncology 1999;71(2):130-5.
-
1999: McCarthy K; Maguire T; McGreal G; McDermott E; O'Higgins N; Duffy M J
High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer.
International journal of cancer. Journal international du cancer 1999;84(1):44-8.
-
1998: Shering S G; Sherry F; McDermott E W; O'Higgins N J; Duffy M J
Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma.
Cancer 1998;83(12):2521-7.
-
1998: Sweep C G; Geurts-Moespot J; Grebenschikov N; de Witte J H; Heuvel J J; Schmitt M; Duffy M J; Jänicke F; Kramer M D; Foekens J A; Brünner N; Brugal G; Pedersen A N; Benraad T J
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
British journal of cancer 1998;78(11):1434-41.
-
1998: Maguire T M; Shering S G; Duggan C M; McDermott E W; O'Higgins N J; Duffy M J
High levels of cathepsin B predict poor outcome in patients with breast cancer.
The International journal of biological markers 1998;13(3):139-44.
-
1998: Duffy M J; Duggan C; Mulcahy H E; McDermott E W; O'Higgins N J
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
Clinical chemistry 1998;44(6 Pt 1):1177-83.
-
1998: Kennedy S; Duffy M J; Duggan C; Barnes C; Rafferty R; Kramer M D
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
British journal of cancer 1998;77(10):1638-41.
-
1998: Duffy M J
CA 19-9 as a marker for gastrointestinal cancers: a review.
Annals of clinical biochemistry 1998;35 ( Pt 3)():364-70.
-
1998: Remacle A G; Noël A; Duggan C; McDermott E; O'Higgins N; Foidart J M; Duffy M J
Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.
British journal of cancer 1998;77(6):926-31.
-
1997: Skelly M M; Troy A; Duffy M J; Mulcahy H E; Duggan C; Connell T G; O'Donoghue D P; Sheahan K
Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1837-40.
-
1997: Maguire T M; Shering S G; McDermott E W; O'Higgins N; Fennelly J J; Crown J; Duffy M J
Assay of E-cadherin by ELISA in human breast cancers.
European journal of cancer (Oxford, England : 1990) 1997;33(3):404-8.
-
1997: Duggan C; Kennedy S; Kramer M D; Barnes C; Elvin P; McDermott E; O'Higgins N; Duffy M J
Plasminogen activator inhibitor type 2 in breast cancer.
British journal of cancer 1997;76(5):622-7.
-
1996: Chenard M P; O'Siorain L; Shering S; Rouyer N; Lutz Y; Wolf C; Basset P; Bellocq J P; Duffy M J
High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma.
International journal of cancer. Journal international du cancer 1996;69(6):448-51.
-
1996: Duffy M J
PSA as a marker for prostate cancer: a critical review.
Annals of clinical biochemistry 1996;33 ( Pt 6)():511-9.
-
1996: Duffy M J; Duggan C; Maguire T; Mulcahy K; Elvin P; McDermott E; Fennelly J J; O'Higgins N
Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer.
Enzyme & protein 1996;49(1-3):85-93.
-
1995: Duffy M J
Can molecular markers now be used for early diagnosis of malignancy?
Clinical chemistry 1995;41(10):1410-3.
-
1995: Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly J J; Duffy M J
Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
International journal of cancer. Journal international du cancer 1995;61(5):597-600.
-
1995: Duffy M J; Blaser J; Duggan C; McDermott E; O'Higgins N; Fennelly J J; Tschesche H
Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer.
British journal of cancer 1995;71(5):1025-8.
-
1995: Coveney E C; Geraghty J G; Sherry F; McDermott E W; Fennelly J J; O'Higgins N J; Duffy M J
The clinical value of CEA and CA 15-3 in breast cancer management.
The International journal of biological markers 1995;10(1):35-41.
-
1994: Duffy M J; Reilly D; McDermott E; O'Higgins N; Fennelly J J; Andreasen P A
Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer.
Cancer 1994;74(8):2276-80.
-
1994: Nugent A; Gallagher J; Dolan J; O'Higgins N; Duffy M J
Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer.
Annals of clinical biochemistry 1994;31 ( Pt 2)():171-3.
-
1992: Geraghty J G; Coveney E C; Sherry F; O'Higgins N J; Duffy M J
CA 15-3 in patients with locoregional and metastatic breast carcinoma.
Cancer 1992;70(12):2831-4.
-
1992: Duffy M J; Reilly D; Brouillet J P; McDermott E W; Faul C; O'Higgins N; Fennelly J J; Maudelonde T; Rochefort H
Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival.
Clinical chemistry 1992;38(10):2114-6.
-
1992: Nugent A; McDermott E; Duffy K; O'Higgins N; Fennelly J J; Duffy M J
Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer.
Clinical chemistry 1992;38(8 Pt 1):1471-4.
-
1992: Nugent A; McDermott E; O'Higgins N; Fennelly J J; Duffy M J
Measurement of erbB-2 oncoprotein in human breast cancers by ELISA.
Biochemical Society transactions 1992;20(1):82S.
-
1991: Reilly D; Andreasen P; Duffy M J
Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level.
Biochemical Society transactions 1991;19(1):44S.
-
1991: Duffy M J; Brouillet J P; Reilly D; McDermott E; O'Higgins N; Fennelly J J; Maudelonde T; Rochefort H
Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings.
Clinical chemistry 1991;37(1):101-4.
-
1990: Duffy M J; Reilly D; O'Sullivan C; O'Higgins N; Fennelly J J; Andreasen P
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.
Cancer research 1990;50(21):6827-9.
-
1990: Duffy M J; Reilly D; O'Sullivan C; O'Higgins N; Fennelly J J
Urokinase plasminogen activator and prognosis in breast cancer.
Lancet 1990;335(8681):108.
-
1989: Duffy M J
New cancer markers.
Annals of clinical biochemistry 1989;26 ( Pt 5)():379-87.
-
1988: Duffy M J; O'Grady P; Devaney D; O'Siorain L; Fennelly J J; Lijnen H J
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
Cancer 1988;62(3):531-3.
-
1988: Duffy M J; O'Grady P; Devaney D; O'Siorain L; Fennelly J J; Lijnen H R
Tissue-type plasminogen activator, a new prognostic marker in breast cancer.
Cancer research 1988;48(5):1348-9.
-
1987: Duffy M J
Do proteases play a role in cancer invasion and metastasis?
European journal of cancer & clinical oncology 1987;23(5):583-9.
-
1986: Duffy M J; O'Siorain L; Waldron B; Smith C
Estradiol receptors in human breast carcinomas assayed by use of monoclonal antibodies.
Clinical chemistry 1986;32(10):1972-4.
-
1985: O'Grady P; Lijnen H R; Duffy M J
Multiple forms of plasminogen activator in human breast tumors.
Cancer research 1985;45(12 Pt 1):6216-8.
-
1984: Duffy M J; O'Grady P
Plasminogen activator and cancer.
European journal of cancer & clinical oncology 1984;20(5):577-82.
Sign-in to see more
